Analyst Recommendations
Here’s a quick look at ratings for TriSalus Life Sciences and its competitors.
| Sell | Hold | Buy | Strong Buy | Score | |
| TriSalus Life Sciences | 0 | 0 | 4 | 0 | 3.00 |
| Competitors | 1662 | 4404 | 8408 | 251 | 2.49 |
TriSalus has a price target of $12.50, suggesting a 198.33% upside. In comparison, competitors in the “Surgical & medical instruments” sector have a 17.60% upside. Analysts favor TriSalus over its peers.
Volatility & Risk
TriSalus has a beta of 0.47, making its stock 53% less volatile than the S&P 500. Rivals average a beta of 0.53, indicating they are 47% less volatile.
Valuation and Earnings
Comparing revenue and earnings:
| Gross Revenue | Net Income | P/E Ratio | |
| TriSalus | $24.74 million | -$59.04 million | -1.68 |
| Competitors | $875.84 million | $47.94 million | -1.12 |
Competitors generate more revenue and profits, yet TriSalus has a lower P/E ratio, indicating it may be more affordable.
Profitability
Here’s how they stack up:
| Net Margins | Return on Equity | Return on Assets | |
| TriSalus | -219.71% | N/A | -192.99% |
| Competitors | -575.50% | -141.13% | -25.81% |
Ownership
2.6% of TriSalus shares are held by institutions; 47.4% in the industry. Company insiders own 76.2% of shares, versus 15.9% industry-wide, indicating strong confidence in the company.
Summary
TriSalus lags behind its competitors in 7 out of 13 metrics assessed.
Company Profile
Founded in 2009, TriSalus Life Sciences develops drug delivery technologies for liver and pancreatic cancer treatments. Their products include infusion systems and investigational therapeutics for various cancer types.
Receive daily news and ratings for TriSalus Life Sciences.
`
